Interpretation of long-term survival data from MONARCH 3. Letter to the Editor regarding " Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2-advanced breast cancer: final overall survival results of MONARCH 3" by M. P. Goetz et al.

被引：0
|
作者：
Sherry, A. D. [1 ]
Lin, T. A. [2 ]
McCaw, Z. R. [3 ,4 ]
Ludmir, E. B. [5 ,6 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Div Radiat Oncol, Houston, TX USA
[2] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD USA
[3] Insitro, South San Francisco, CA USA
[4] Univ N Carolina, Dept Biostat, Chapel Hill, NC USA
[5] Univ Texas MD Anderson Canc, Dept Gastrointestinal Radiat Oncol, Div Radiat Oncol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷 / 08期
关键词：
D O I：
10.1016/j.annonc.2024.05.543
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：747 / 748
页数：2
相关论文
共 16 条
  • [1] MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer
    Goetz, Matthew
    Toi, Masakazu
    Huober, Jens
    Sohn, Joo Hyuk
    Tredan, Olivier
    Park, Inhae
    Campone, Mario
    Chen, Shin-Cheh
    Manso, Luis Manual
    Paluch-Shimon, Shani
    Freedman, Orit C.
    Andre, Valerie
    Saha, Abhijoy
    van Hal, Gertjan
    Shahir, Ashwin
    Iwata, Hiroji
    Johnston, Stephen R. D.
    O'Shaughnessy, Joyce
    Pivot, Xavier
    Tolaney, Sara
    Hurvitz, Sara
    Llombart, Antonio
    CANCER RESEARCH, 2024, 84 (09)
  • [2] To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding ' Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HRD, HER2L advanced breast cancer: Final overall survival results of MONARCH 3'
    Orlandi, A.
    Mastrantoni, L.
    Bria, E.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2024, 35 (08)
  • [3] MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)
    Goetz, M. P.
    Toi, M.
    Huober, J.
    Sohn, J.
    Tredan, O.
    Park, I. H.
    Campone, M.
    Chen, S. C.
    Sanchez, L. M. Manso
    Paluch-Shimon, S.
    van Hal, G.
    Shahir, A.
    Iwata, H.
    Johnston, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1384 - S1384
  • [4] Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HRD, HER2L advanced breast cancer: final overall survival results of MONARCH 3
    Goetz, M. P.
    Toi, M.
    Huober, J.
    Sohn, J.
    Tredan, O.
    Park, I. H.
    Campone, M.
    Chen, S. -C.
    Manso, L. M.
    Paluch-Shimon, S.
    Freedman, O. C.
    O'Shaughnessy, J.
    Pivot, X.
    Tolaney, S. M.
    Hurvitz, S. A.
    Llombart-Cussac, A.
    Andre, V.
    Saha, A.
    van Hal, G.
    Shahir, A.
    Iwata, H.
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2024, 35 (08) : 718 - 727
  • [5] Response to letters to the Editor on 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HRD, HER2L advanced breast cancer: final overall survival results of MONARCH 3'
    Goetz, M. P.
    Andre, V.
    Johnston, S. R. D.
    ANNALS OF ONCOLOGY, 2024, 35 (12) : 1202 - 1204
  • [6] MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis
    Goetz, Matthew P.
    Martin, Miguel
    Di Leo, Angelo
    Im, Seock-Ah
    Awada, Ahmad
    Forrester, Tammy
    Frenzel, Martin
    Cox, Joanne
    Barriga, Susana
    Toi, Masakazu
    Iwata, Hiroji
    Johnston, Stephen
    CANCER RESEARCH, 2018, 78 (13)
  • [7] Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ' Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HRD, HER2L advanced breast cancer: fi nal overall survival results of MONARCH 3' by M. P. Goetz et al
    De Sanctis, R.
    Bruzzi, P.
    Zambelli, A.
    ANNALS OF ONCOLOGY, 2024, 35 (12) : 1201 - 1202
  • [8] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Huang, C-S.
    Toi, M.
    Im, Y-H.
    Iwata, H.
    Sohn, J.
    Wang, H-C.
    Masuda, N.
    Im, S-A.
    Lu, Y.
    Haddad, N.
    Sakaguchi, S.
    Hurt, K.
    Neven, P.
    Llombart-Cussac, A.
    Sledge, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S1258 - S1259
  • [9] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Toi, Masakazu
    Huang, Chiun-Sheng
    Im, Young-Hyuck
    Sohn, Joohyuk
    Zhang, Wei
    Sakaguchi, Sachi
    Haddad, Nadine
    van Hal, Gertjan
    Sledge Jr, George W.
    CANCER SCIENCE, 2023, 114 (01) : 221 - 226
  • [10] Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2-advanced breast cancer
    Goetz, M. P.
    Johnston, S.
    Martin, M.
    Tokunaga, E.
    Park, I. H.
    Huober, J.
    Toi, M.
    Price, G. L.
    Boye, M.
    Li, L.
    Forrester, T.
    Gainford, C.
    Gable, J.
    Carter, G. C.
    Sood, A.
    Dileo, A.
    CANCER RESEARCH, 2019, 79 (04)
12